Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Pembrolizumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-20

Last Posted Date: 2023-08-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 12

Registration Number: NCT02906332

Locations: 🇺🇸
John Theurer Cancer Center-Hackensack Meridian Health, Hackensack, New Jersey, United States

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Phase 2

Completed

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Nivolumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-16

Last Posted Date: 2023-06-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02903381

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Phase 1

Terminated

Conditions: B Cell Lymphoma
Lymphoma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2016-09-13

Last Posted Date: 2022-09-26

Lead Sponsor: Brian Hill

Target Recruit Count: 19

Registration Number: NCT02898259

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-13

Last Posted Date: 2020-11-12

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 46

Registration Number: NCT02897830

Locations: 🇫🇷
University Hosptial Toulouse, Toulouse, France

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Thalidomide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-29

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 124

Registration Number: NCT02891811

Locations: 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹
Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹
Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria

and more 18 locations

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Phase 1

Active, not recruiting

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Hiltonol
Drug: Citarinostat
Biological: PVX-410
Drug: Lenalidomide

First Posted Date: 2016-09-01

Last Posted Date: 2024-04-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 19

Registration Number: NCT02886065

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Phase 2

Completed

Conditions: Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Pembrolizumab

First Posted Date: 2016-08-26

Last Posted Date: 2019-07-30

Lead Sponsor: Mayo Clinic

Target Recruit Count: 11

Registration Number: NCT02880228

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Relapsed Hodgkin Lymphoma
Relapsed Non-Hodgkin Lymphoma

Interventions: Biological: Pembrolizumab
Drug: Lenalidomide

First Posted Date: 2016-08-23

Last Posted Date: 2020-08-14

Lead Sponsor: NYU Langone Health

Target Recruit Count: 6

Registration Number: NCT02875067

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
NYU Perlmutter Cancer Center, New York, New York, United States

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2016-08-22

Last Posted Date: 2023-07-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 224

Registration Number: NCT02874742

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Phase 2

Completed

Conditions: Ann Arbor Stage II Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Fever
Bulky Disease
Night Sweats
Ann Arbor Stage II Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Fatigue
Weight Loss
Ann Arbor Stage IV Grade 1 Follicular Lymphoma

Interventions: Drug: Lenalidomide
Biological: Obinutuzumab

First Posted Date: 2016-08-18

Last Posted Date: 2024-07-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT02871219

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy